Axon Enterprise (NASDAQ:AXON) Releases Quarterly Earnings Results

Axon Enterprise (NASDAQ:AXON) released its quarterly earnings results on Tuesday. The biotechnology company reported $999.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.65 by $997.35, Zacks reports. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%.

Axon Enterprise Trading Up 4.7%

Shares of NASDAQ:AXON traded up $19.96 during trading on Tuesday, reaching $443.40. 899,958 shares of the stock were exchanged, compared to its average volume of 927,314. The firm’s 50-day moving average price is $542.06 and its 200 day moving average price is $631.57. The firm has a market cap of $34.99 billion, a price-to-earnings ratio of 140.32, a price-to-earnings-growth ratio of 13.07 and a beta of 1.48. Axon Enterprise has a 12-month low of $396.41 and a 12-month high of $885.91. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: DHS nationwide body‑camera initiative could materially increase institutional demand for Axon’s cameras and Evidence.com platform — a clear revenue and TAM catalyst. DHS Body Camera Plan Puts Axon’s Growth Potential And Valuation In Focus
• Positive Sentiment: Analysts remain broadly bullish and cite strong Axon momentum, international traction and ecosystem growth — supporting upside expectations and likely helping today’s rally. Do Wall Street Analysts Like Axon Enterprise Stock?
• Neutral Sentiment: Q4 2025 earnings preview: Axon reports after the close; investors will focus on revenue growth, subscription/ARR trends, margin progress and FY26 guidance — any guidance weakness or upside could swing the stock. Axon Enterprise Earnings Preview: What Wall Street Is Watching
• Neutral Sentiment: Multiple earnings previews (Benzinga, 24/7 Wall St.) reiterate the same watchpoints — these set expectations but don’t yet move fundamentals until results/guidance arrive. Axon Enterprise’s Earnings: A Preview
• Neutral Sentiment: Liquidation of leveraged ETFs that tracked Axon (AXUP) could create short‑term mechanical flows; likely limited long‑term impact but adds noise to price action. Liquidation of T-REX 2X LONG UPXI Daily Target ETF (PXIU), T-REX 2X LONG AXON Daily Target ETF (AXUP), and T-REX 2X LONG BKNG Daily Target ETF (BKNU)
• Negative Sentiment: Short‑term bearish narrative: a Forbes piece highlights a 29% pullback from late January and asks whether AXON could fall to $300 — this frames downside risk and can pressure sentiment. Can Axon Stock Fall To $300?
• Negative Sentiment: Needham cut its price target to $600, a reminder that some sell‑side shops are trimming upside as shares trade off — negative for near‑term sentiment given the stock’s elevated valuation. Needham & Company LLC Cuts Axon Enterprise (NASDAQ:AXON) Price Target to $600.00

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AXON. William Blair restated an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 3rd. Barclays lowered their price objective on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Piper Sandler reduced their target price on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. UBS Group lowered their price target on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating for the company in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a report on Monday, December 29th. Fifteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average target price of $786.43.

Insider Activity

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 1,797 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $539.23, for a total transaction of $968,996.31. Following the completion of the sale, the insider directly owned 83,485 shares in the company, valued at $45,017,616.55. The trade was a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $551.92, for a total transaction of $5,519,200.00. Following the completion of the sale, the chief executive officer directly owned 3,110,997 shares of the company’s stock, valued at $1,717,021,464.24. The trade was a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 48,040 shares of company stock valued at $27,249,338 over the last quarter. 4.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Axon Enterprise

Hedge funds have recently modified their holdings of the stock. Sunbelt Securities Inc. increased its stake in shares of Axon Enterprise by 324.1% in the fourth quarter. Sunbelt Securities Inc. now owns 123 shares of the biotechnology company’s stock worth $70,000 after buying an additional 94 shares during the last quarter. Corient Private Wealth LLC grew its holdings in Axon Enterprise by 579.2% during the 4th quarter. Corient Private Wealth LLC now owns 65,447 shares of the biotechnology company’s stock worth $37,169,000 after acquiring an additional 55,811 shares in the last quarter. Strive Financial Group LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter valued at about $41,000. Raymond James Financial Inc. lifted its position in shares of Axon Enterprise by 0.8% during the fourth quarter. Raymond James Financial Inc. now owns 404,990 shares of the biotechnology company’s stock worth $231,015,000 after purchasing an additional 3,136 shares during the last quarter. Finally, Vident Advisory LLC grew its stake in Axon Enterprise by 15.3% in the fourth quarter. Vident Advisory LLC now owns 4,145 shares of the biotechnology company’s stock worth $2,354,000 after purchasing an additional 550 shares in the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.